July 31, 2014

Teva Pharmaceuticals on Thursday announced results for second-quarter 2014, which included revenues of $5 billion, an increase of 2% compared with the same period last year.

July 14, 2014

Teva Pharmaceuticals on Monday announced that the Food and Drug Administration has accepted the company's new drug application for albuterol multi-dose dry-powder inhaler, a breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease.

June 20, 2014

Teva has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) Inhalation aerosol product.

October 23, 2013

The Food and Drug Administration plans to complete its phase out of inhalers that contain ozone-depleting chlorofluorocarbons by the end of the year, the agency said Wednesday.

May 1, 2013

Teva Pharmaceutical Industries has launched a generic inhaler used to treat bronchospasm, the company said.

March 18, 2013

The Food and Drug Administration has approved a generic treatment for bronchospasm made by Mylan, the drug maker said Monday.

January 3, 2013

An inhaler for patients with bronchospasm that includes a dose counter has become available from Teva Respiratory, the company said Thursday.

September 7, 2012

Perrigo is seeking regulatory approval for what it called the first generic version of a drug for treating bronchospasm.

August 20, 2012

Prasco Labs is distributing an authorized generic version of a respiratory drug under an agreement with the branded drug's manufacturer.

July 30, 2012

Generic drug maker Watson Pharmaceuticals is challenging the patent protection on a drug for acne and a drug for bronchospasm, the company said Monday.

June 21, 2012

Taken together, asthma and chronic obstructive pulmonary disease — which includes chronic bronchitis and emphysema — affect nearly 50 million Americans, or about 15% of the total U.S. population, according to statistics from such organizations as the Centers for Disease Control and Prevention.

May 29, 2012

A unit of generic drug maker Mylan has settled with Sunovion Pharmaceuticals over a drug used to treat chronic obstructive pulmonary disease and asthma.

March 9, 2012

The Food and Drug Administration has approved a version of a drug made by Teva that includes a dose counter, the drug maker said.

February 14, 2012

Generic drug maker Mylan plans to challenge a court decision that requires it to pay almost $20 million to a drug company whose product it tried to market as a generic.

October 10, 2011

The Food and Drug Administration has approved a new product for chronic obstructive pulmonary disease made by Boehringer Ingelheim Pharmaceuticals, the drug maker said.

March 16, 2011

The Food and Drug Administration on Wednesday announced that the only over-the-counter asthma inhaler sold in the United States no longer will be available as of Dec. 31 as part of an international agreement to stop the use of substances that damage the environment.

April 12, 2010

The Food and Drug Administration will start phasing out asthma and chronic obstructive pulmonary disease...